Target

TTR

Transthyretin

Also: ATTR

56open trials
106trials in total
144publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
23 Nov 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
PET/CT Imaging in Carriers of TTR Mutations
14 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Hereditary ATTR amyloidosis in Italy: pathogenic variant patterns and clinical profiles from a multicenter genetic dataset.
5 Nov 2026· Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology· PUBMED
Publication
Long-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label Extension.
3 Nov 2026· Circulation· PUBMED
Publication
Operational definitions of the asymptomatic TTR variant carrier: a methodological framework for ATTRv amyloidosis polyneuropathy research.
3 Nov 2026· Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis· PUBMED
Trial
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
1 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor
30 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Prognosis of Native T1 Mapping in TTR Amyloid Cardiomyopathy: Beaten to the Finish Line by Extracellular Volume.
29 Oct 2026· JACC. Cardiovascular imaging· PUBMED
Publication
Reply to 'the illusion of improvement in ATTR-CM: re-evaluating informative missingness and discordant endpoints in ATTRibute-CM'.
28 Oct 2026· European journal of heart failure· PUBMED
Publication
Towards the diagnostic scores we need in ATTR-CM: Editorial for the article: Comparison of three scoring systems in the identification of transthyretin cardiac amyloidosis in a HFpEF cohort.
27 Oct 2026· International journal of cardiology· PUBMED
Publication
Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study.
21 Oct 2026· Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis· PUBMED
Publication
Discovery of Neutral and Cerebrospinal Fluid Penetrant Transthyretin (TTR) Stabilizers with Heterocyclic Linkers.
8 Oct 2026· Journal of medicinal chemistry· PUBMED
Publication
Identifying Suspected ATTR-CM From Unstructured EHR Data Using AI.
1 Oct 2026· JACC. Advances· PUBMED
Publication
Automated echocardiographic measurements for longitudinal monitoring of ATTR cardiomyopathy: agreement and repeatability analysis.
29 Sept 2026· The international journal of cardiovascular imaging· PUBMED
Publication
Pathophysiology and Comprehensive Pharmacological Management of ATTR Cardiac Amyloidosis: Knowledge Gaps, Ongoing Clinical Trials, and Future Research Directions.
29 Sept 2026· Pharmaceuticals (Basel, Switzerland)· PUBMED
Publication
Clinical Significance of Time in Therapeutic Range (TTR) During Unfractionated Heparin Therapy in Non-ST-Segment Elevation Myocardial Infarction.
28 Sept 2026· Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis· PUBMED
Trial
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis
23 Sept 2026· NA · RECRUITING· CTGOV
Publication
Apolipoprotein A-IV Cardiac Amyloidosis: Beyond ATTR and AL.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
Abnormal Cardiac PET Imaging in ATTR Amyloidosis.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
Transthyretin Amyloidosis Due to a Rare TTR Val142del Deletion With Relatively Early Clinical Manifestations.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
ATTR-CM in Patients With Clinically Significant Plasma Cell Dyscrasias: A Case Series Highlighting Diagnostic Challenges.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
TTR Variant p.Ala65Val Causing Early-Onset Hereditary Transthyretin Amyloidosis With Mixed Cardiac and Neuropathic Phenotype.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
Rare Hereditary Cardiac Amyloidosis Treated With SGLT2 Inhibitor: Beyond ATTR/AL.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
Successful Heart Transplantation in a Patient With Triple Infiltrative Cardiomyopathy: Sarcoidosis, AL and TTR Amyloidosis.
23 Sept 2026· JACC. Case reports· PUBMED
Publication
Comparative Effectiveness of TTR Stabilizers for the Treatment of ATTR-CM Using Real-World Evidence.
23 Sept 2026· Cardiology and therapy· PUBMED
Publication
Specific treatment of ATTR-CM in Germany-expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK).
22 Sept 2026· Clinical research in cardiology : official journal of the German Cardiac Society· PUBMED
Publication
A Phenotype Risk Score-Triggered E-Visit Pathway to Capture TTR V142I in a Heart Failure Population.
16 Sept 2026· JACC. Case reports· PUBMED
Publication
Acoramidis for ATTR cardiomyopathy: value, access, and the duty to treat.
16 Sept 2026· European heart journal. Quality of care & clinical outcomes· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error